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Abstract
Background: Improved helminth control is required to alleviate the global burden of schistosomiasis and schistosome-
associated pathologies. Current control efforts rely on the anti-helminthic drug praziquantel (PZQ), which enhances immune
responses to crude schistosome antigens but does not prevent re-infection. An anti-schistosome vaccine based on
Schistosoma haematobium glutathione-S-transferase (GST) is currently in Phase III clinical trials, but little is known about the
immune responses directed against this antigen in humans naturally exposed to schistosomes or how these responses
change following PZQ treatment.
Methodology: Blood samples from inhabitants of a Schistosoma haematobium-endemic area were incubated for 48 hours
with or without GST before (n = 195) and six weeks after PZQ treatment (n = 107). Concentrations of cytokines associated
with innate inflammatory (TNFa, IL-6, IL-8), type 1 (Th1; IFNc, IL-2, IL-12p70), type 2 (IL-4, IL-5, IL-13), type 17 (IL-17A, IL-21, IL-
23p19) and regulatory (IL-10) responses were quantified in culture supernatants via enzyme-linked immunosorbent assay
(ELISA). Factor analysis and multidimensional scaling were used to analyse multiple cytokines simultaneously.
Principal Findings: A combination of GST-specific type 2 (IL-5 and IL-13) and regulatory (IL-10) cytokines was significantly
lower in 10–12 year olds, the age group at which S. haematobium infection intensity and prevalence peak, than in 4–9 or
13+ year olds. Following PZQ treatment there was an increase in the number of participants producing detectable levels of
GST-specific cytokines (TNFa, IL-6, IL-8, IFNc, IL-12p70, IL-13 and IL-23p19) and also a shift in the GST-specific cytokine
response towards a more pro-inflammatory phenotype than that observed before treatment. Participant age and pre-
treatment infection status significantly influenced post-treatment cytokine profiles.
Conclusions/Significance: In areas where schistosomiasis is endemic host age, schistosome infection status and PZQ
treatment affect the cellular cytokine response to GST. Thus the efficacy of a GST-based vaccine may also be shaped by the
demographic and epidemiological characteristics of targeted populations.
Citation: Bourke CD, Nausch N, Rujeni N, Appleby LJ, Trottein F, et al. (2014) Cytokine Responses to the Anti-schistosome Vaccine Candidate Antigen
Glutathione-S-transferase Vary with Host Age and Are Boosted by Praziquantel Treatment. PLoS Negl Trop Dis 8(5): e2846. doi:10.1371/journal.pntd.0002846
Editor: William Evan Secor, Centers for Disease Control and Prevention, United States of America
Received September 18, 2013; Accepted March 25, 2014; Published May 8, 2014
Copyright:  2014 Bourke et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by the Wellcome Trust UK (Grant no: WT082028MA, http://www.wellcome.ac.uk/); the University of Edinburgh Moray
Endowment Fund; the World Health Organization (Grant no: RPC264); Cunningham Trust; and Carnegie Trust for the Universities of Scotland (http://www.
carnegie-trust.org/). CDB was funded by a studentship from the BBSRC and a travel grant from the British Society of Parasitology Garnham Expeditionary Fund. FM
and NN are funded by the Thrasher Research Fund and Schistosome Control Initiative. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Claire.bourke@york.ac.uk
¤a Current address: Centre for Infection & Immunology, Department of Biology, University of York, York, United Kingdom
¤b Current address: University of Zimbabwe, College of Health Sciences, Department of Medical Microbiology, Avondale, Harare, Zimbabwe
Introduction
Over 200 million people in 74 countries are currently infected
with Schistosoma spp. parasites, which are responsible for an
estimated 15, 000 deaths and 1.76 million disability adjusted life
years per annum [1–3]. Schistosoma haematobium is the causative
agent of urogenital schistosomiasis which results from pathological
immune responses to eggs excreted into the bladder and genital
tract of their host by adult parasites residing in the adjacent
venules. Effective schistosome control is required to alleviate
schistosome-associated pathologies, to protect the 650 million
people currently at risk from schistosome infection and to reach
the estimated 88% of infected people currently without access to
drug treatment [2,4]. Current control efforts rely on treatment
with the anti-helminthic drug praziquantel (PZQ), which has
reported cure rates of over 80% [5,6] and can reduce the risk of
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urogenital lesions if administered during childhood [7]. There is
also mounting evidence that PZQ boosts both innate and adaptive
immune responses to schistosome antigens [8–10] due to increased
worm death in the bloodstream and an associated increase in
exposure of schistosome antigens to immune recognition after
treatment [11,12]. However, although there is some evidence that
this immunological boost promotes a degree of resistance to re-
infection in humans [10,13], both infection prevalence and
associated pathologies return after treatment and therefore
repeated treatment is required [14,15]. For nearly 30 years an
anti-schistosome vaccine has been seen as a desirable long-term
adjunct to drug treatment [3,16]. More recently, it has been
proposed that a combination of PZQ treatment and an anti-
pathology vaccine may improve schistosome control [12,16,17].
The 28 KDa S. haematobium vaccine candidate antigen glutathi-
one-S-transferase (GST [18,19]) is a multifunctional enzyme
expressed on the tegument and sub-tegument of adult worms
[20] and larval schistosomes [21] and the current focus of vaccine
trials in humans. The exact function of schistosome GST is
unknown but its role in fatty acid metabolism and prostaglandin
D2 synthesis may contribute to immune evasion by the parasite
[19]. GST-based vaccination has been extensively studied in
animal models, leading to a reduction in parasite fecundity in
cattle [22], goats [23] and primates [24], which has been
attributed to production of antibodies that neutralise GST enzyme
activity [25–27]. Importantly, reducing egg production by adult
schistosomes is an effective means of reducing immunopathology
since schistosomes do not replicate in their definitive hosts [3]. The
latter is supported by observations in S. haematobium infected Patas
monkeys where bladder lesion intensity was reduced following
GST vaccination [24,28]. A recent Phase I randomised clinical
study has shown that elevated levels of GST-neutralising
antibodies, which are associated with reduced parasite fecundity
[25,29], as well as increased peripheral blood cytokine responses
were detectable 21 days after a double dose of the GST vaccine
was administered to healthy Caucasian adult males [30].
Furthermore, GST-specific PBMC cytokine responses in the latter
study appeared to be biased towards a CD4+ T helper (h) 2
phenotype [30], which is associated with protective immune
responses to schistosome homogenate antigens in cohorts endem-
ically-exposed to S. haematobium [31,32]. Despite these promising
observations in animal models and safety-immunogenicity trials in
humans in a non-endemic setting, very little is known about the
cellular immune phenotype elicited by purified GST in naturally
schistosome-exposed populations who would be the target
recipients of a GST-based vaccine. In particular, GST-specific
cytokine responses have been investigated in S. haematobium-
exposed adults [33], but no studies to date have investigated the
age-distribution of GST-specific cellular cytokine responses which
is closely related to schistosome exposure history [11,34].
Furthermore, despite speculation that GST-based vaccine efficacy
may be enhanced by co-administration with PZQ in human
populations [12,16,17,35] there is no existing data on how PZQ
treatment affects GST-specific cytokine responses.
The aim of this study was to address two previously un-
addressed hypotheses regarding cellular cytokine responses to
purified GST in an S. haematobium-endemic community: firstly that
these responses vary with age (and by proxy, exposure to infection
[34]), and secondly that they are boosted by PZQ treatment.
Importantly, we have made use of statistical approaches that
integrate data on multiple cross-regulatory cytokines associated
with relevant cellular immune phenotypes (innate inflammatory,
Th1, Th2, Th17 and regulatory responses) so that our analysis
considers not only the dynamics of individual GST-specific
cytokines, but also their patterns of production relative to one
another.
Methods
Ethical permissions
Ethical approval was granted by the Medical Research Council
of Zimbabwe and the University of Zimbabwe’s Institutional
Review Board. Local permission for the study was granted by the
Provincial Medical Director of Mashonaland East. All prospective
participants were informed of the study aims and procedures in
their local language (Shona). All adult participants provided
informed written consent and children were recruited only if
informed written consent was provided by a parent or guardian.
Study design
The current study is part of on-going schistosome immuno-
epidemiological research in Murehwa District, Mashonaland East
province, Zimbabwe where S. haematobium is endemic [36–38].
Pre-studies in the area showed that S. mansoni and soil-transmitted
helminth (STH) prevalence is low (,2%) and the region is
classified as a low transmission area for Plasmodium spp. [39]. The
study area had not been included in previous PZQ treatment
programs. Baseline recruitment of participants was school-based
but pre-school age children and adults were also informed of the
study and invited to attend via community meetings prior to the
commencement of baseline sampling.
The following samples were collected from all recruited
participants (n = 284); 1) a minimum of 2 urine samples collected
over 3 consecutive days for quantification of S. haematobium
infection intensity, 2) a minimum of 2 stool samples collected over
3 consecutive days for quantification of soil-transmitted helminth
(STH) and S. mansoni infections, and 3) 10 ml venous blood.
Participants also completed a questionnaire to assess residential
history, patterns of exposure to schistosome infective water and
anti-helminthic drug treatment history. Participants were excluded
Author Summary
Schistosomiasis is caused by infection with Schistosoma
spp. parasites, for which the main treatment is the drug
praziquantel (PZQ). Since PZQ does not prevent reinfec-
tion, an anti-schistosome vaccine based on the Schistoso-
ma haematobium enzyme glutathione-S-transferase (GST)
is being developed. In this study we investigated the GST-
specific immune responses of people naturally exposed to
schistosomes and the affect that PZQ has on these
responses. We cultured blood samples from a schisto-
some-exposed community with GST before and six weeks
after PZQ treatment and measured a range of soluble
proteins (cytokines) in culture supernatants as indicators of
blood cell activation and phenotype. Before treatment,
GST-specific cytokine responses varied with host age,
particularly in children with high intensity schistosome
infections. Following treatment, GST activated blood
samples from more individuals to produce a broader
range of cytokines and the combination of GST-specific
cytokine responses reflected a more pro-inflammatory
immune phenotype than that observed pre-treatment.
Post-treatment responses varied according to host age
and pre-treatment infection status. Taken together, our
study suggests that current and future GST-based vaccine
trials should take host age, schistosome infection status
and PZQ treatment history into account since these factors
influence GST-specific immune activation.
Human Cytokine Responses to Schistosome GST
PLOS Neglected Tropical Diseases | www.plosntds.org 2 May 2014 | Volume 8 | Issue 5 | e2846
from the study if: they did not provide samples 1–3 (n = 5), they
provided insufficient blood volume for stimulation with GST and a
control culture without antigen (n = 13) or quantification of all
cytokines (n = 25), they indicated in their questionnaire responses
that they were not life-long permanent residents of the study area
(n = 23), or they were positive for STH (n = 0), S. mansoni (n = 5),
HIV (n = 18) or Plasmodium spp. infection (n = 0).
After baseline sampling all compliant participants were treated
with a single dose of PZQ (40 mg/kg body weight) and sampling
was repeated 6 weeks post-treatment. For inclusion in the post-
treatment cohort participants were required to provide a full set of
samples 1–3 and remain negative for all co-infections 6 weeks post-
treatment (n = 126). Ten eligible participants refused PZQ
treatment for religious reasons and 9 eligible participants remained
positive for S. haematobium infection following treatment, these
participants were excluded from the post-treatment cohort. Based
on these criteria, a total of 195 participants were included in the
baseline cohort and, of these, 107 participants made up the post-
treatment cohort. Re-infection was assessed at 6 and 18 months
post-treatment in participants who provided samples 1 and 2 at
these timepoints (n = 75). High community-wide prevalence and
infection intensity at baseline precluded inclusion of an untreated
control group according to WHO treatment guidelines [40].
Diagnostic tests
Stool and urine samples were collected and processed following
the standard microscopic procedures (Kato Katz for stool and
urine filtration methods for urine) [41,42]. Infection intensity was
expressed as the mean egg count per 10 ml urine for S. haematobium
calculated from a minimum of 2 samples/participant before
treatment, and 6 weeks, 6 months and 18 months post-treatment.
Plasmodium spp. and HIV infection were identified serologically as
previously described [10].
Schistosome antigens
Recombinant 28 KDa GST of a Senegalese strain of S.
haematobium was cloned and purified using previously described
protocols [43]. GST preparations were confirmed to be endotoxin
free (,0.015 EU/ml) using the Limulus amebocyte lysate assay
(Sigma-Aldrich, Lyon, France).
Whole blood culture
Venous blood samples were collected from study participants
into EDTA-coated tubes and cultured at a 1:3 dilution with media
(RPMI 1640 supplemented with 2 mM L-glutamine and 100 U
Penicillin/Streptomycin (all Lonza, Verviers, Belgium)) in dupli-
cate wells coated with either 2 mg/ml GST or without antigen (i.e.
culture media alone) for 48 hours at 37uC in Anaerogen Compact
anaerobic atmosphere generation pouches (OXOID, Basingstoke,
U.K.). Cell-free culture supernatants were frozen and assayed
within 12 months.
Cytokine ELISA
Interferon (IFN) c, Tumour necrosis factor (TNF) a, Inter-
leukin(IL)-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13 and
IL-21 (BD Biosciences, Oxford, U.K.), IL-17A and IL23p19
(eBiosciences Ltd., Hatfield, U.K.) were assayed in culture
supernatants via enzyme-linked immunosorbent assay (ELISA)
using published protocols [10].
Statistical analysis
S. haematobium infection intensity exhibited a negatively skewed
distribution within the study cohort as is typical of schistosome
infection in endemic populations [44]. Infection intensity was
therefore log10(x+1) transformed and compared for infected
participants by gender (male and female) and age group (4–9,
10–12 and 13+ years) via ANOVA (adjusted sums of squares).
Post-hoc pairwise comparisons between the 3 age groups were
made using Fisher’s least significant difference test.
Cytokine levels present in culture supernatants were not
normally distributed even following transformation, therefore all
comparisons of cytokine levels were conducted using non-
parametric statistical tests. Cytokine levels in GST-stimulated
cultures were compared to those present in parallel cultures
without antigen from the same individuals via the paired Wilcoxon
test. Cytokine levels present in un-stimulated culture supernatants
were then subtracted from those present in GST-stimulated
cultures to give GST-specific cytokine levels. Where an individual
did not produce a cytokine at levels above those in their parallel
un-stimulated culture they were assigned a value of 0 pg/ml for
that cytokine. The percentage of GST-specific cytokine producers
(i.e. levels above those in un-stimulated cultures) was compared by
gender, age group and S. haematobium infection status via Pearson’s
Chi-squared test. Comparisons between the percentage of GST-
specific cytokine producers pre- and 6 weeks post-treatment were
made using the paired McNemar’s test. To confirm that
treatment-related differences in cytokine responses were not due
to sampling bias in the smaller post-treatment cohort, baseline
GST-specific cytokine levels were compared between participants
included in post-treatment follow up analyses and those that were
not included using the Mann Whitney U test (p.0.05 for all 13
cytokine responses; data not shown).
GST-specific cytokine responses were reduced into a smaller
number of variables (principal components, PCs) according to
their shared patterns of expression via factor analysis as previously
reported [10]. Due to the skewed nature of GST-specific cytokine
responses (i.e. few producers for some cytokines and a non-normal
distribution of cytokine levels) values were log10(x+1) transformed
to minimise the influence of outlier values [45] and only GST-
specific cytokines that were detectable in .30% of participants
were included in the factor analyses. Dynamics of cytokines with a
factor loading $0.5 or #20.5 onto a PC were considered to be
reflected by that PC. Separate factor analyses were conducted for
baseline (Table S1) and 6 weeks post-treatment cytokine responses
(Table S2). PC regression factor scores at each timepoint were
compared by gender, age group and S. haematobium infection status
via ANOVA. Sequential sums of squares were used to account for
demographic variation (gender and age group) before infection
status.
To characterise changes in the distribution of GST-specific
cytokine responses for each participant 6 weeks after treatment
relative to pre-treatment levels non-metric multidimensional
scaling (NMS) was used to provide a visual representation of
similarity/dissimilarity between participant responses. NMS was
conducted as described previously [10,46] and the non-parametric
multiple response permutation procedure (MRPP) was used to
statistically compare pre- and post-treatment cytokine profiles.
Pearson’s correlation analysis was used to determine the amount of
variation between participant NMS scores that were attributable
to each spatial axis. Non-parametric Kendall correlations analysis
was used to identify associations between NMS spatial axes and
the original concentrations of the 13 individual cytokines. A
cytokine was considered to be reflected by the spatial axis if
Kendall’s tau (t) $0.4.
Statistical tests were conducted using SPSS Statistics version 19
software (IBM, Hampshire, U.K.) and NMS was implemented
using PC-ORD software (MJM Software Design, Gleneden Beach,
Human Cytokine Responses to Schistosome GST
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U.S.A.) [46]. Comparisons were considered to be significant at p,
0.05. Where .10 comparisons were made the p-value was
adjusted for multiple comparisons via the sequential Bonferroni
correction and comparisons that were significant post-correction
were considered highly significant.
Results
S. haematobium infection distribution in the study cohort
The baseline study cohort consisted of 94 males and 101 females
ranging in age from 4–84 years. Baseline S. haematobium infection
prevalence was 52.3%. A higher percentage of men (58.5%) than
women (46.5%) were S. haematobium positive at baseline, and of the
infected individuals men had a significantly higher mean infection
intensity than women (Figure 1A; F1, 96: 6.56, p = 0.012). S.
haematobium infection intensity also showed a non-linear relation-
ship with age (Figure 1B: F2, 96: 4.00, p = 0.021) as is typical of
schistosome epidemiology [44], with infection intensity peaking in
children aged 10–12 years (4–9 vs. 10–12 years: Mean difference:
20.385, p = 0.028; 13+ vs. 10–12 years: Mean difference: 20.486,
p = 0.007). The demographic and S. haematobium infection charac-
teristics of the study cohort are summarised in Table 1.
GST-specific cytokine responses vary with age
All cytokines were present at significantly higher levels in GST-
stimulated whole blood cultures than in corresponding un-
stimulated cultures (p,0.001 for Wilcoxon comparisons of all 13
cytokines; data not shown) indicating that a specific cytokine
response to S. haematobium GST was elicited within the cohort.
Only 4.6% of participants (n = 9) produced no detectable GST-
specific cytokines at levels greater than those present in un-
stimulated cultures (Table 1).
Having established that GST elicited a whole blood cytokine
response, we next sought to characterise demographic factors that
may influence these responses. We first compared the percentage
of participants producing GST-specific cytokines and found no
difference according to gender or infection status in any of the
cytokines measured (Table 2). However, when compared by age,
the youngest age group (4–9 years) was found to have a
significantly higher percentage of GST-specific IL-4 (X2: 14.08,
p = 0.001) and IL-10 (X2: 8.49, p = 0.014) producers than either
the 10–12 or 13+ year age groups (Figure S1, Table 2).
In addition to the presence/absence of individual cytokines, the
relative levels of different cross-regulatory cytokines could also be
an important determinant of the GST-specific immune response.
Figure 1. Distribution of S. haematobium infection in the study cohort. Infection prevalence (%) and intensity (Log10(x+1) transformed mean
egg counts/10 ml urine) sub-divided by gender (A) and age group (B). Mean values are indicated by horizontal bars. Significance levels from ANOVA
(adjusted sums of squares) of infection intensity for infected participants are shown for gender and post-hoc pair-wise Fisher’s least significant
difference comparisons are shown for the 3 age groups (n = 101);*p,0.005, **p,0.01.
doi:10.1371/journal.pntd.0002846.g001
Table 1. Demographic and S. haematobium infection characteristics of the study cohort by age group.
Age group (years)
4–9 10–12 13+
n 77 34 84
Gender Males, Females 38, 39 18, 16 38, 46
Age Mean 6 SEM 7.2560.15 11.3560.12 26.9262.11
S. haematobium infection intensity Mean egg counts 6 SEM (min.-max.) 24.0468.70 (0–481) 86.85628.61 (0–692) 12.8765.10 (0–403)
S. haematobium prevalence Prevalence (%) 53.2 67.6 45.2
GST-specific cytokines Producersa (%) 97.4 94.1 94.0
aDetectable GST-specific cytokine production.levels present in un-stimulated cultures for $1 of the 13 cytokines assayed.
doi:10.1371/journal.pntd.0002846.t001
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To characterise patterns of GST-specific cytokines, all cytokines
produced by.30% of participants (i.e. IFNc, TNFa, IL-5, IL-6, IL-
8, IL-10, IL-12p70, IL-13, IL-21 and IL23p19), were reduced into
PCs according to their shared patterns of expression via factor
analysis. This analysis identified 3 key patterns of GST-specific
cytokine response accounting for variation between participants;
PC1 accounted for the largest amount of variation (28.5%) and
corresponded to pro-inflammatory cytokine responses (IFNc,
TNFa, IL-6, IL-8, IL-12p70 and IL23p19), PC2 corresponded to
a combination of Th2 (IL-5 and IL-13) and regulatory (IL-10)
responses and PC3 reflected expression of the neutrophil chemoat-
tractant (IL-8) and was negatively associated with the Th1 cytokine
IFNc (for factor loadings refer to Table S1). None of these cytokine
patterns varied according to participant gender or infection status
(Figure 2; Table 3), however PC2 significantly differed between the
3 age groups (Figure 2; F2, 188: 6.940, p = 0.001). Pair-wise
comparisons between age groups indicated that PC2 scores were
significantly lower in 10–12 year olds than in either 4–9 (Mean
difference:20.678, p = 0.002) or 13+ year olds (Mean difference:2
0.777, p,0.001) indicating a lower Th2/regulatory cytokine
response to GST in this group. PCs 1 and 3 did not significantly
differ between the 3 age groups (Figure 2; Table 3).
Anti-helminthic treatment boosts cytokine production in
response to GST
Laboratory studies have proposed that co-administration of a
GST-based vaccine with PZQ may promote vaccine efficacy
[12,16,17], therefore we investigated whether naturally-acquired
GST-specific cytokine responses are affected by PZQ treatment.
Six weeks after a single dose of PZQ there was a significant
increase relative to baseline in the percentage of participants
producing detectable levels of GST-specific cytokines associated
with innate inflammatory (TNFa, IL-6 and IL-8), Th1 (IFNc, IL-2
Figure 2. Distribution of pre-treatment GST-specific cytokine profiles by gender, age group and S. haematobium infection status.
Mean principal component regression factor scores for pro-inflammatory (PC1), Th2/regulatory (PC2) and innate inflammatory/Th1 (PC3) cytokine
profiles sub-divided by gender (A), age group (B) and schistosome infection status (C; un-infected= egg negative in all urine samples, infected= egg
positive in one or more urine samples). Where ANOVA (sequential sums of squares accounting for variation in gender and age group before infection
status) indicated that a factor significantly contributed to variation in cytokine profiles, pair-wise comparisons of PC scores were conducted via post-
hoc Fisher’s least significant difference tests between the 3 age groups (n = 195);**p,0.01, ***p,0.001. Error bars: standard error of the mean.
doi:10.1371/journal.pntd.0002846.g002
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and IL-12p70), Th2 (IL-13) and Th17 (IL-23p19) immune
responses (Figure S2; Table 4).
In addition to an increase in the proportion of individuals
producing cytokines in response to GST, we also investigated
whether there was a post-treatment shift in combined cytokine
responses to GST relative to pre-treatment patterns. The latter is
an important addition to our understanding of GST-specific
immune responses since post-treatment cytokine phenotype
appears to be a determinant of resistance to re-infection both in
human population studies [10,47] and murine models of
schistosomiasis [48]. To visualise this comparison NMS was used
to position each participant along two spatial axes according to
their levels of all 13 GST-specific cytokines relative to those of all
other participants both before and 6 weeks after treatment. Thus
participants with similar combinations of GST-specific cytokines
are arranged close together and those with dissimilar responses are
further apart. The ordination plots of this analysis showed that
pre- and post-treatment cytokine responses formed distinct clusters
reflecting a shift in the whole blood cytokine responses elicited by
GST (Figure 3) and this dissimilarity between pre- and post-
treatment cytokine responses was statistically significant (MRPP;
T: 253.438, p,0.001, A: 0.062). Kendall’s correlation between
the original cytokine levels and the NMS spatial axes indicated
that the majority of variation in pre- and post-treatment cytokine
responses was attributable to the increase in levels of IFNc (t:
0.449), TNFa (t: 0.508), IL-6 (t: 0.782), IL-8 (t: 0.544), IL-12p70
(t: 0.500) and IL23p19 (t: 0.617) 6 weeks after treatment (Axis 2;
Pearson’s r2: 0.492). To a lesser extent pre- and post-treatment
cytokine responses also varied along Axis 1 (Pearson’s r2: 0.236),
which was positively correlated with IL-6 (t: 0.440) and negatively
correlated with IL-21 (t: 20.391). These cytokines are associated
with innate inflammatory and effector Th1 and Th17 responses
and thus the phenotype of the post-treatment cytokine response to
GST is more pro-inflammatory than at baseline.
Post-treatment cytokine responses vary according to
host age and pre-treatment infection status
Post-treatment cytokine responses produced in response to GST
stimulation by .30% of participants (i.e. IFNc, TNFa, IL-2, IL-5,
IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-21 and IL23p19) were
reduced into post-treatment cytokine profiles via factor analysis
(for factor loadings refer to Table S2). Similar to patterns observed
before treatment, the majority of variation (32.5%) between post-
treatment responses was due to differences in pro-inflammatory
cytokine responses (IFNc, TNFa, IL-6, IL-8, IL-12p70 and
IL23p19; PC1). Variation was also evident in a combination of
IL-2, IL-10, IL-13 and IL-21 levels, reflecting responses associated
with Th2, regulatory and Th17 cells (PC2; 13.2% of variance),
and a profile that was positively associated with the type 2 effector
cytokine IL-5 and negatively associated with the regulatory
cytokine IL-10 (PC3; 10.0% of variance). Post-treatment PC1
significantly differed according to participant age group (Figure 4,
Table 3; F2, 102: 3.547, p = 0.032) with the youngest participants
having significantly higher scores than those in the 10–12 (Mean
difference: 0.516, p = 0.049) or 13+ age groups (Mean difference:
0.508, p = 0.026). Post-treatment PC2 scores significantly differed
according to infection status at baseline and were lower in
participants with patent infection at the time of treatment than in
their schistosome-negative counterparts (Figure 4, Table 3; F1, 102:
6.070, p = 0.015), suggesting that the presence of live parasites at
the time of treatment influenced levels of Th2, Th17 and
regulatory type cytokines 6 weeks later. PC3 scores were not
significantly affected by participant gender, age group or pre-
treatment infection status (Figure 4, Table 3).
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Re-infected children have lower GST-specific IL-12p70
post-treatment
It has been proposed that higher post-treatment schistosome-
specific cytokine responses to schistosome antigens promote
resistance to re-infection [10,31] and we therefore sought to
investigate whether GST-specific cytokine responses differed
between participants who were re-infected within 18 months of
treatment and those who remained un-infected. Only 7 partici-
pants within the cohort were re-infected within 18 months of
treatment (4 males, 3 females, aged 7–13 years) and we therefore
compared their 6 week post-treatment GST-specific cytokine
responses to those of 7 un-infected children matched according to
age, gender and pre-treatment infection status and intensity (Table
S3; intensity matched by 657.34 eggs, no other age- and gender-
matched participants within the post-treatment cohort matched
the pre-infection intensity of the re-infected participants). Of the
13 cytokines assayed, only post-treatment GST-specific IL-12p70
levels differed significantly between the two groups (Figure 5; Z: 2
1.992, p = 0.046, not significant after Bonferroni adjustment for
multiple comparisons). GST-specific IL-12p70 levels were lower in
the re-infected child than in the age-, gender- and pre-treatment
infection intensity-matched child that remained uninfected post-
treatment in 5 of the 7 pairs, higher in one pair, and the same in
one pair of children (Figure 5).
Discussion
S. haematobium GST has been extensively characterised as a
vaccine candidate antigen for urogenital schistosomiasis in
laboratory models and has also advanced further along the
vaccine development pathway than any of the other potential anti-
schistosome vaccines [3,16,30]. Despite the efficacy of GST
vaccination in animal models [25,26] and immunogenicity in
clinical trials [30] the phenotype of the cellular immune response
to GST in populations endemically exposed to S. haematobium has
been largely uncharacterised. The latter is particularly the case for
innate inflammatory, regulatory and Th17 associated immune
markers due to the relatively recent characterisation of the role
played by these immune phenotypes in human schistosomiasis
[10,49,50]. The current study addresses this gap in our
understanding of how GST-specific whole blood cytokine
responses, including cytokines associated with innate inflammatory
(TNFa, IL-6 and IL-8), Th1 (IFNc, IL-2 and IL-12p70), Th2 (IL-
4, IL-5 and IL-13), Th17 (IL-17A, IL-21 and IL-17A) and
regulatory (IL-10) immune phenotypes, are distributed both before
and after PZQ treatment in an S. haematobium-endemic commu-
nity.
High intensity schistosome infections tend to be aggregated in
school-age children and are comparatively lower in adults
indicating that the relationship between infection intensity,
exposure history and infection-related immune responses change
with age [34]. However, the only study that has quantified
cytokine responses to GST in schistosome-exposed humans
focused on adults [33]. We therefore investigated a wider range
of ages (4–84 years) with the hypothesis that GST-specific cytokine
responses would vary between 3 age groups reflecting age-
dependent changes in S. haematobium infection distribution;
increasing intensity of infection (4–9 year olds), peaking infection
intensity (10–12 year olds) and declining infection intensity (13+
year olds). Exclusion of co-infected and non-permanent residents
of the study area meant that all participants included in this age
stratified analysis had experienced life-long exposure to infection
and thus their age was considered a proxy for their history of
exposure to S. haematobium [34,51].
Our results show that whole blood samples from untreated
schistosome-exposed participants of all ages produce detectable
cytokine responses to GST stimulation, which is consistent with
observations that immune responses to GST develop naturally in
both resistant and susceptible individuals [27,33,52] and are
evident from a young age [52]. In contrast, whole blood samples
from schistosome and GST naı¨ve people do not produce
detectable levels of cytokines in responses to stimulation with
Table 4. Paired comparison of the percentage of participants producing detectable levels of GST-specific cytokines before and 6
weeks after PZQ treatment.
%Cytokine Producers McNemar’s test (p)
Pre-treatment (n =107) Post-treatment (n =107) df:1
Innate Inflammatory TNFa 40.6 76.4 #0.001***
IL-6 76.4 92.5 0.002**
IL-8 44.3 91.5 #0.001***
Th1 IFNc 35.8 71.7 #0.001***
IL-2 27.4 47.2 0.005**
IL-12p70 32.1 71.7 #0.001***
Th2 IL-4 20.8 23.6 0.749
IL-5 38.7 43.4 0.568
IL-13 32.1 61.3 #0.001***
Th17 IL-17A 18.9 30.2 0.096
IL-21 43.4 55.7 0.124
IL-23 61.3 93.4 #0.001***
Regulatory IL-10 43.4 42.5 1
Cytokines are categorised according to the cellular phenotype with which they are most commonly associated. McNemar’s test (paired data, binomial distribution): p-
values,0.05 are indicated in bold and those significant after Bonferroni correction for multiple comparison are indicated by underlined text,
**p,0.01,
***p,0.001.
doi:10.1371/journal.pntd.0002846.t004
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GST in vitro [30]. We also demonstrate that participant age
contributes to variation in GST-specific cytokine responses in a
schistosome-endemic context by affecting both the capacity to
produce different types of GST-specific cytokines and patterns of
co-produced cytokines. The highest percentage of GST-specific
IL-4, a Th2-associated cytokine, and IL-10, a regulatory cytokine,
producers was in the youngest age group (4–9 years), which may
reflect the more regulatory schistosome-specific immune profile of
individuals with a short history of schistosome exposure. For
example, at younger ages, the proportion of circulating T
regulatory cells (Treg) is more positively associated with S.
haematobium infection intensity than in older age groups (14+
years) in whom this relationship is negatively correlated [49]. We
also found that a combined phenotype of Th2 (IL-5 and IL-13)
and regulatory (IL-10) cytokine responses to GST (PC2) was lowest
in children aged 10–12 years in whom infection intensity and
prevalence are peaking, suggesting that this may be a particularly
dynamic period in terms of GST exposure and development of
GST-specific cellular immune responses. Taken together these
observations indicate that the Th2-type responses most associated
with protective immunity in previous studies (i.e. IL-4 and IL-5
[30,31]) are also the most age-dependent. Therefore, GST-based
vaccine efficiency should be assessed across a range of ages during
trials in schistosome-exposed populations in order to generate
accurate predictions of population efficacy. An important area for
future research will be to identify GST-specific cytokine-producing
cell types within the whole blood milieu and determine whether
these cells are influenced by host age and schistosome infection
intensity.
Interestingly neither GST-specific whole blood cytokine pro-
duction nor phenotype differed according to gender despite
evidence of a gender bias in both neutralising antibody and PBMC
cytokine responses identified in previous studies in adults
endemically exposed to S. haematobium [33] and S. mansoni [27].
At baseline, cytokine responses also did not differ between
individuals without infection and those with S. haematobium
infection who might be expected to have stronger cytokine
responses to GST due to on-going exposure to live adult worms.
We also found no significant correlation between pre-treatment
GST-specific cytokine profiles (PCs 1–3) and S. haematobium
infection intensity (data not shown). The absence of an infection-
related difference in GST-specific cytokines may be due to the fact
that many abundant somatic antigens (including GST) are
sequestered from the immune system by live schistosome worms
[9,11,52]. Therefore, recall responses of whole blood cells to GST
stimulation in vitro may be more closely related to a person’s history
of exposure to dying worms than to the presence or absence of live
worms in the bloodstream [11], as described for age-related
Figure 3. Relative similarity and dissimilarity in patterns of GST-specific cytokine responses before and 6 weeks after praziquantel
treatment. NMS ordination plot showing Sorensen Bray-Curtis distance scores (an indicator of how a participant’s combination of 13 GST-specific
cytokine responses rank relative to those of all other participants) for all participants plotted before (grey triangles) and 6 weeks after (red
triangles) praziquantel treatment. Axis 1 and 2 are spatial meaning that participants positioned close together have similar patterns of cytokine
responses to GST and those positioned far apart have dissimilar patterns of cytokine responses to GST. The individual cytokines that most closely
correlate with each axis are indicated. Bold diamonds represent the mean pre- (grey) and post-treatment (red) scores for the study cohort (n = 107).
doi:10.1371/journal.pntd.0002846.g003
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patterns of GST-specific cytokine responses above. It is also
possible that exposure of un-infected individuals (i.e. egg negative
urine samples) to GST-expressing schistosome larvae which do not
develop into fecund adult worm pairs is sufficient to elicit similar
GST-specific cytokine responses to those of individuals harbouring
patent infections (i.e. egg positive urine samples) [53].
Given that PZQ treatment results in a specific increase in the
intensity of GST recognition by serum antibodies [9] in addition
to a generalised increase in immune responsiveness to whole adult
schistosome homogenates [10], we were interested to see whether
GST-specific cytokine profiles changed post-treatment. Six weeks
after treatment we observed a dramatic increase in the percentage
of participants producing detectable GST-specific levels of all
innate inflammatory (TNFa, IL-6 and IL-8) and Th1-associated
(IFNc, IL-2 and IL-12p70) cytokines, as well as the effector Th2-
associated cytokine IL-13 and the Th17-associated cytokine IL-
23p19 (i.e. cytokines associated with pro-inflammatory and
effector immune responses). Reflecting this boost in pro-inflam-
matory cytokine responses after treatment, a clear shift was evident
in the combined pattern of GST-specific responses after PZQ
treatment relative to baseline. The NMS analysis used to show this
pattern was particularly informative since it incorporated all 13
GST-specific cytokines for each individual into a single analysis
[46] and thus avoided focusing on variation in individual cytokines
which are inherently cross-regulatory and therefore non-indepen-
dent [54]. NMS has the added benefit of being based on relative
Figure 4. Distribution of post-treatment GST-specific cytokine profiles by gender, age group and S. haematobium infection status.
Mean post-treatment principal component regression factor scores for cytokine profiles associated with pro-inflammatory (post-treatment PC1), Th2/
Th17/regulatory (post-treatment PC2) and Th2/regulatory (post-treatment PC3) responses sub-divided by gender (A), age group (B) and schistosome
infection status at baseline (C; un-infected= egg negative in all urine samples, infected= egg positive in one or more urine samples). Error bars:
standard error of the mean. Where ANOVA (sequential sums of squares accounting for variation in gender and age group before infection status)
analysis indicated that age group contributed to variation in cytokine profiles, pair-wise comparisons of PC scores were conducted via post-hoc
Fisher’s least significant difference tests between the 3 age groups (n = 107);*p,0.05.
doi:10.1371/journal.pntd.0002846.g004
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Figure 5. Levels of 6 weeks post-treatment GST-specific cytokines in children who remained un-infected and those who were re-
infected within 18 months of treatment. The levels GST-specific (pg/ml, untransformed) cytokines associated with innate inflammatory (top
row), Th1 (second row), Th2 (third row), Th17 (fourth row) and regulatory (fifth row) responses produced 6 weeks after treatment by un-
infected children (grey diamonds) and age, gender and pre-treatment infection intensity-matched children who were re-infected (red diamonds)
within 18 months of treatment (i.e. $1 S. haematobium egg in any of their urine samples collected 6 months and 18 months post-treatment). Lines
join age, sex and infection intensity matched pairs and details of the characteristics of each pair are provided in Table S3. Results of paired Wilcoxon
comparison between un-infected (n = 7) and re-infected children (n = 7) are indicated, *p,0.05.
doi:10.1371/journal.pntd.0002846.g005
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differences in cytokine responses (i.e. each NMS score is based on
levels of all 13 cytokines ranked relative to those of the rest of the
cohort [46]) rather than quantitative differences between individ-
uals and thus the analysis is not biased towards abundant cytokines
which are not necessarily more bioactive than those present at low
concentrations (e.g. cytokine bioactivity is dependent on cytokine
receptor expression in addition to cytokine concentration [54]).
Ours is the first study to show that GST-specific cytokine responses
are boosted by PZQ treatment but our observations are consistent
with previous observations in the same Zimbabwean community
that PZQ treatment leads to an increase in pro-inflammatory
cytokine responses to antigens from whole S. haematobium cercariae
and eggs, which both express GST [10]. Both the intensity of GST
recognition and the range of GST isoforms bound by serum
antibodies are also enhanced in PZQ-treated inhabitants of
schistosome-endemic areas relative to that observed before
treatment [9], supporting our observations of a boost in cellular
responsiveness specifically to GST after treatment. Increased levels
of schistosome-specific cytokines have also been observed follow-
ing treatment of S. mansoni-exposed populations, although cyto-
kines associated with innate inflammatory and Th17 responses
were not assayed in these studies [8,13].
Following treatment, the 4–9 years age group had the highest
scores for pro-inflammatory cytokine profiles relative to the older
age groups. Thus, children with the least exposure to schistosome
infection and the most regulatory responses to crude schistosome
antigens prior to treatment [49] experience the most prominent
boost in pro-inflammatory cytokine responses to GST post-
treatment. A more pronounced post-treatment increase in children
relative to adults has previously been observed for antibody
responsiveness to schistosome antigens [55]. PZQ treatment also
resulted in schistosome infection-related differences in post-
treatment GST-specific Th2-/Th17-/regulatory-type cytokine
responses, which were lower in participants with patent infection
at the time of treatment than in their un-infected counterparts.
The difference between infected and uninfected participant
cytokine responses after, but not before treatment, likely reflects
the pronounced increase in GST exposure resulting from a PZQ-
mediated adult worm death in infected but not uninfected
individuals [9,11]. For example, the relative shift away from a
Th2/Th17/regulatory profile following treatment of infected but
not uninfected participants may result from a rapid decline in Th2
cells and immunosuppressive mechanisms following removal of
live parasites, as described in previous studies [50,55].
Few participants were re-infected within 18 months of treatment
(n = 7), however we observed that GST-specific IL-12p70
responses were lower in these re-infected children than in their
gender, age and pre-treatment infection intensity-matched coun-
terparts who remained uninfected. Although the number of
participants included in this analysis is too low to draw firm
conclusions on the influence of GST-specific cytokine responses on
re-infection rates, this pattern is consistent with our previous
observations in the same community that lower pro-inflammatory
whole blood cytokine responses to S. haematobium egg antigens are
associated with a higher risk of re-infection [10]. Assaying GST-
specific cytokine responses over a longer period after PZQ
treatment or in communities experiencing more intense re-
infection rates are required to identify whether GST-specific
cytokine responses contribute to schistosome re-infection risk.
Collectively this study offers the first comprehensive character-
isation of the distribution of GST-specific cytokine responses at a
population level in humans naturally exposed to schistosome infection.
Our results indicate that GST-specific cytokine profiles are influenced
by participant age and PZQ treatment and post-treatment cytokine
responses to GST are also influenced by pre-treatment infection
intensity. Thus these factors may influence cellular responses to a GST
vaccine formulation and should be taken into consideration in future
immunogenicity and efficacy trials.
Supporting Information
Figure S1 Distribution of the percentage production
and levels of individual GST-specific cytokine responses
by age group. The percentage of participants producing
detectable amounts of GST-specific cytokines associated with
innate inflammatory (top row), Th1 (second row), Th2 (third
row), Th17 (fourth row) and regulatory (fifth row) type cellular
immune phenotypes and the levels of these cytokines produced
(pg/ml, untransformed) in the 4–9, 10–12 and 13+ age groups at
baseline (n = 195). Median values are indicated by horizontal bars.
Pearson’s Chi-squared comparisons of percentage production
between age groups and by gender and S. haematobium infection
status are provided in Table 2.
(TIF)
Figure S2 GST-specific cytokine production before and
6 weeks after praziquantel treatment. The percentage of
participants producing detectable amounts of GST-specific
cytokines associated with innate inflammatory (top row), Th1
(second row), Th2 (third row), Th17 (fourth row) and
regulatory (fifth row) type cellular immune phenotypes and the
levels of these cytokines produced (pg/ml, untransformed) before
(grey triangles) and 6 weeks after (red triangles) a single dose
of praziquantel (n = 107). Median values are indicated by
horizontal bars. McNemar comparisons of percentage production
before and after treatment are provided in Table 4.
(TIF)
Table S1 Factor analysis of GST-specific cytokine
responses before anti-helminthic treatment. aFactor
loadings for each PC (columns) are indicated for individual
cytokines (arranged in rows according to the cellular immune
phenotype with which they aremost commonly associated).
Cytokines with factor loadings $0.5 or #20.5 were considered
to significantly contribute to the PC (underlined). *bGST-specific
cytokines produced by ,30% of participants were not included in
the factor analysis.
(DOCX)
Table S2 Factor analysis of GST-specific cytokine
responses 6 weeks post-treatment. aFactor loadings for
each PC (columns) are indicated for individual cytokines (arranged
in rows according to the cellular immune phenotype with which
they are most commonly associated). Cytokines with factor
loadings $0.5 or #20.5 were considered to significantly
contribute to the PC (underlined). *bGST-specific cytokines
produced by ,30% of participants were not included in the
factor analysis.
(DOCX)
Table S3 Characteristics of children re-infected within
18 months of treatment and their age-, sex- and S.
haematobium infection-matched pairs who remained
un-infected post-treatment.
(DOCX)
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